Captrust Financial Advisors Cyto Dyn Inc. Transaction History

Captrust Financial Advisors

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 23, 2022	SELL	$0.24 - $0.51 $726 - $1,542	-3,025 Reduced 16.28%	15,551 $7,000
Q1 2022 May 16, 2022	SELL	$0.37 - $1.02 $925 - $2,550	-2,500 Reduced 11.86%	18,576 $7,000
Q4 2021 Feb 14, 2022	SELL	$0.98 - $1.86 $7,399 - $14,043	-7,550 Reduced 26.37%	21,076 $21,000
Q3 2021 Nov 16, 2021	BUY	$1.27 - $2.46 $4,763 - $9,227	3,751 Added 15.08%	28,626 $57,000
Q2 2021 Aug 16, 2021	BUY	$1.67 - $3.98 $14,592 - $34,777	8,738 Added 54.15%	24,875 $42,000
Q1 2021 May 17, 2021	BUY	$2.12 - $7.15 $31,429 - $105,998	14,825 Added 1129.95%	16,137 $44,000
Q2 2020 Aug 14, 2020	BUY	$2.25 - $8.77 $2,952 - $11,506	1,312 New	1,312 $9,000

321K

Ticker CYDY
Exchange OTC
Sector Healthcare
Industry Biotechnology
Shares Outstandng 813,040,000
Market Cap $236M
Description
CytoDyn Inc. operates as a clinical-stage biotechnology company. The company focuses on developing treatments for multiple therapeutic indications based on leronlimab, a novel humanized monoclonal antibody targeting the CCR5 receptor in the areas of human immunodeficiency virus (HIV), non-alcoholic steatohepatitis (NASH), oncology, and such as c...

Get notified when there are updates to the investment portfolio of Captrust Financial Advisors, based on Form 13F filings with the SEC.

Stay updated on Captrust Financial Advisors with notifications on news.